proton therapy

Penn Medicine and Belgian proton therapy company IBA have announced a joint venture to support the development of proton therapy and radiation oncology programs worldwide. The partnership aims to help hospitals and clinics internationally establish and expand advanced cancer treatment services, combining Penn Medicine's clinical expertise with IBA's technology. The announcement has been picked up by financial and international news outlets.

Penn Medicine and Belgian proton therapy firm IBA have formed a joint venture aimed at advancing proton therapy and radiation oncology. The partnership will focus on developing and expanding access to advanced radiation treatments for cancer patients. Announced via trade press coverage in medical imaging and technology outlets, the collaboration is being watched for its potential impact on cancer care delivery.

IBA and Penn Medicine have announced a joint venture called the Noventra Oncology Alliance, combining the particle therapy technology company's expertise with the academic medical center's clinical and research capabilities. The partnership is aimed at advancing cancer treatment, though further details about its scope, funding and first projects have not yet been made widely available.